Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Sean Whittier

University of Kansas Lawrence, Department: Pharmacology

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

Hafion, LLC

Disclosed Value
Listed Reason
Salary not from the awardee Institution

Dr. Whittier is the Hafion PI for the subcontract associated with this project. Dr. Whittier is a part-time KU Associate Researcher, and employed, part-time, as a Hafion scientist. He does not report to the (KU) PI of this project in his KU role. Dr. Wendy Picking is Hafion CEO and (KU) PI on this project. This project was included in Dr. Whittier’s management plan to ensure appropriate separation between University and company role and resources.

Listed Research Project
Vaccines to counter emerging antibiotic resistance

Vaccination may be the greatest public health achievement of our time. As antibiotic resistance becomes more prevalent among pathogenic bacteria, vaccines will become even more important, however, many vaccines being developed only work against a narrow range of bacteria, even within a single genus or species, due to being ?serotype-specific.? To overcome this limitation, we have developed a new vaccine strategy that provides protection across serotype, strain and species boundaries. This nanoparticle-antigen platform will provide broad protection against pathogenic Shigella, Salmonella and Pseudomonas. Furthermore, it will provide preventative measure that overcomes the increasing development of antibiotic resistance in these important pathogens.

Filed on July 30, 2018.

Tell us what you know about Sean Whittier's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page